Join Dr. Michael Abramoff MD, PhD as he joins a panel at AAO. The symposium will cover 1) the use and equity of artificial intelligence (AI) devices for diabetic retinopathy grant results; 2) AI’s impact on administrative tasks and processes; 3) generative AI: benefits, limitations and safeguards; 4) international perspective on AI; and 5) the FDA perspective on AI: issues in regulatory decision-making.
Artificial Intelligence: How it could change clinical care, administration, and research, and the perspective of FDA